CD16-B Activators
CD16-B activators constitute a diverse group of chemical compounds that enhance the functional activity of the CD16-B protein through various intracellular signaling pathways. For instance, Bisindolylmaleimide, as a selective inhibitor of protein kinase C, impedes the phosphorylation-associated downregulation of CD16-B, thereby sustaining its activity levels. Similarly, the action of Forskolin, by increasing intracellular cAMP, can enhance CD16-B functionality through PKA-dependent mechanisms, ensuring an amplified response to ligand binding. ProstaglandinE2, engaging with the EP4 receptor, activates downstream PI3K/Akt pathways, which then act to stabilize and activate CD16-B, impeding its internalization and degradation. The calcium ionophore Ionomycin raises intracellular calcium levels, indirectly promoting CD16-B activity by simulating the activation of calcium-dependent pathways. Additionally, Thapsigargin, by inhibiting the SERCA pump, also elevates cytosolic calcium levels, leading to the enhancement of CD16-B signaling.
The modulation of CD16-B activity is further influenced by compounds that target specific kinases involved in its regulation. Piceatannol and U0126 work to inhibit Syk kinase and MEK1/2 respectively, removing negative regulation on CD16-B and allowing for an upregulated signaling response. Bryostatin 1, a modulator of PKC, uniquely prolongs CD16-B activation by altering phosphorylation patterns without triggering downregulation. SB 203580 and PD98059, both inhibitors of elements within the MAPK pathway, lift the suppression of CD16-B signaling, thus promoting its activity. Dibutyryl-cAMP, by mimicking the effect of elevated cAMP, activates PKA, which in turn enhances CD16-B signaling. Lastly, LY294002, while inhibiting PI3K, disrupts negative feedback loops, resulting in a net increase in CD16-B activity, exemplifying how inhibitors of signaling pathways can sometimes lead to the unexpected enhancement of downstream proteins such as CD16-B. All these compounds work in a concerted manner to amplify the functional activity of CD16-B, albeit through distinct biochemical routes, showcasing the complexity of intracellular signaling and regulation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide is a potent and selective inhibitor of protein kinase C (PKC). By inhibiting PKC, it prevents the phosphorylation and subsequent downregulation of CD16-B. This leads to enhanced activity of CD16-B as it remains in a state conducive to binding immune complexes. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) engages the EP4 receptor, which in turn can lead to the activation of downstream signaling cascades such as the PI3K/Akt pathway. This activation can promote the stabilization and activation of CD16-B by preventing its internalization and degradation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP can enhance the functional activity of CD16-B through PKA-dependent signaling pathways, leading to increased affinity and/or avidity for its ligands. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. This elevation can mimic signaling events leading to the activation of pathways that enhance the surface expression and function of CD16-B, facilitating its role in immune complex binding. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol inhibits the Syk kinase, which is involved in the negative regulation of CD16-B signaling. Inhibition of Syk can relieve its suppressive effects, resulting in the enhancement of CD16-B-mediated signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium levels, similar to ionomycin. It can potentiate signaling pathways that result in the functional upregulation of CD16-B, promoting its activity in immune response. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a PKC modulator that can lead to the prolonged activation of CD16-B by altering the phosphorylation status of proteins involved in its signaling cascade, enhancing its activity without promoting downregulation typically associated with PKC activators. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which can indirectly enhance the activity of CD16-B by blocking negative regulatory elements within the MAPK pathway, thus allowing CD16-B signaling to proceed unimpeded. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that can permeate cell membranes and mimic the effects of elevated cAMP within the cell. By doing so, it can activate PKA and enhance CD16-B signaling through phosphorylation events that increase its functional activity in immune processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can paradoxically enhance CD16-B signaling by perturbing negative feedback mechanisms that usually restrain CD16-B activity. By inhibiting PI3K, LY294002 can lead to compensatory responses in cells that result in the activation of CD16-B. | ||||||